Mary Albrecht

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc A randomized clinical trial evaluating therapeutic drug monitoring (TDM) for protease inhibitor-based regimens in antiretroviral-experienced HIV-infected individuals: week 48 results of the A5146 study
    Mary Albrecht
    Beth Israel Deaconess Medical Center, Boston, MA, USA
    HIV Clin Trials 12:201-14. 2011
  2. pmc Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results
    Paul E Sax
    Division of Infectious Diseases, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Infect Dis 204:1191-201. 2011
  3. pmc Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy
    Paul E Sax
    Division of Infectious Diseases and the Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 361:2230-40. 2009
  4. pmc No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy
    Rajesh T Gandhi
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Infect Dis 201:293-6. 2010
  5. pmc Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection
    Judith J Lok
    Center for Biostatistics in AIDS Research, Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    AIDS 24:1867-76. 2010
  6. pmc Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146
    Xinyan Zhang
    Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts, USA
    Ther Drug Monit 35:209-16. 2013
  7. ncbi request reprint Comparing megestrol acetate therapy with oxandrolone therapy for HIV-related weight loss: similar results in 2 months
    D Mkaya Mwamburi
    Division of Geographic Medicine and Infectious Diseases, Tufts New England Medical Center, Boston, Massachusetts 02111, USA
    Clin Infect Dis 38:895-902. 2004
  8. ncbi request reprint Assessing resistance costs of antiretroviral therapies via measures of future drug options
    Hongyu Jiang
    Department of Biostatistics, Statistical and Data Analysis Center, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    J Infect Dis 188:1001-8. 2003

Collaborators

Detail Information

Publications8

  1. pmc A randomized clinical trial evaluating therapeutic drug monitoring (TDM) for protease inhibitor-based regimens in antiretroviral-experienced HIV-infected individuals: week 48 results of the A5146 study
    Mary Albrecht
    Beth Israel Deaconess Medical Center, Boston, MA, USA
    HIV Clin Trials 12:201-14. 2011
    ..Secondary analyses through 48 weeks are presented...
  2. pmc Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results
    Paul E Sax
    Division of Infectious Diseases, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Infect Dis 204:1191-201. 2011
    ..Due to higher virologic failure with ABC/3TC in the high HIV RNA stratum, blinded treatment was stopped in this group, but study follow-up continued for all patients...
  3. pmc Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy
    Paul E Sax
    Division of Infectious Diseases and the Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 361:2230-40. 2009
    ....
  4. pmc No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy
    Rajesh T Gandhi
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Infect Dis 201:293-6. 2010
    ..The stability of the latent reservoir despite intensive therapy suggests that new strategies are needed to eradicate HIV-1 from this reservoir. (ClinicalTrials.gov identifier: NCT00051831 .)...
  5. pmc Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection
    Judith J Lok
    Center for Biostatistics in AIDS Research, Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    AIDS 24:1867-76. 2010
    ..We estimated the long-term CD4 cell count trajectory accounting for losses-to-follow-up and treatment discontinuations...
  6. pmc Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146
    Xinyan Zhang
    Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts, USA
    Ther Drug Monit 35:209-16. 2013
    ..We characterized relationships between ABCB1, CYP3A4, CYP3A5, NR1I2, and SLCO1B1 polymorphisms and trough PI concentrations among AIDS Clinical Trials Group study A5146 participants...
  7. ncbi request reprint Comparing megestrol acetate therapy with oxandrolone therapy for HIV-related weight loss: similar results in 2 months
    D Mkaya Mwamburi
    Division of Geographic Medicine and Infectious Diseases, Tufts New England Medical Center, Boston, Massachusetts 02111, USA
    Clin Infect Dis 38:895-902. 2004
    ..74). In conclusion, megestrol acetate therapy and oxandrolone therapy have similar effects on body weight and composition and are safe and well-tolerated during HAART...
  8. ncbi request reprint Assessing resistance costs of antiretroviral therapies via measures of future drug options
    Hongyu Jiang
    Department of Biostatistics, Statistical and Data Analysis Center, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    J Infect Dis 188:1001-8. 2003
    ..Quantification of future drug options as an outcome of antiretroviral therapy trials may complement traditional clinical, virologic, and immunologic end points, thereby providing novel insights...